Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 17/20 | 0.54 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.54 |
| ▸ | KDR | P35968 | 4/20 | 0.54 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.44 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21726321 | 0.91 | FGFR1 (0.62) | FGFR1FGFR2KDR | |
| SCHEMBL17530567 | 0.84 | KDR (0.52) | FGFR1FGFR2KDRFGFR4FGFR3 | |
| SCHEMBL21726303 | 0.83 | FGFR1 (0.54) | FGFR1FGFR2KDRCSF1R | |
| SCHEMBL17530949 | 0.83 | FGFR1 (0.77) | FGFR1FGFR2KDR | |
| SCHEMBL17530928 | 0.79 | FGFR1 (0.81) | FGFR1FGFR2KDR | |
| SCHEMBL17530541 | 0.77 | FGFR1 (0.78) | FGFR1FGFR2KDRFGFR4FGFR3 | |
| SCHEMBL17530927 | 0.76 | FGFR1 (0.59) | FGFR1FGFR2KDRFGFR4FGFR3 | |
| SCHEMBL17531059 | 0.75 | FGFR1 (0.56) | FGFR1FGFR2KDR | |
| SCHEMBL17530925 | 0.75 | FGFR1 (0.60) | FGFR1FGFR2KDRFGFR4FGFR3 | |
| SCHEMBL17530942 | 0.74 | FGFR1 (0.61) | FGFR1FGFR2KDRFGFR4FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562900-B2 | Indazole compounds as FGFR kinase inhibitor, preparation and use thereof | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2020-02-18 | — | — | US | disclosed |
| US-20170275291-A1 | INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITOR, PREPARATION AND USE THEREOF | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562900-B2 | Indazole compounds as FGFR kinase inhibitor, preparation and use thereof | FGFR1, FGFR2, FGFR3 | FGFR1 1/4885FGFR2 2/4885KDR 236/4885 |
| US-20170275291-A1 | INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITOR, PREPARATION AND USE THEREOF | FGFR1, FGFR2, FGFR3 | FGFR1 1/4885FGFR2 2/4885KDR 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.